Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Hou, Jinxuan ^a,b   Dong, Jixin ^c   Sun, Lijun ^c   Geng, Liying ^c   Wang, Jing ^c   Zheng, Jialin ^c   Li, Yan ^b   Bridge, Julia ^a   Hinrichs, Steven H ^a   Ding, Shi Jian ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; ((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL COMMUNICATION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN CW9019; CELL STRAIN RD; CELL STRAIN RH30; CONTROLLED STUDY; DRUG TARGETING; EMBRYO CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RHABDOMYOSARCOMA; SARCOMA CELL; APOPTOSIS; CELL COUNT; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; INTRACELLULAR SPACE; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; INDOLES; INTRACELLULAR SPACE; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MET; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SULFONAMIDES;

EID: 79955897803     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-64     Document Type: Article

References (37)

1. Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, el-Naggar A. Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg 1995, 112:252-257. 10.1016/S0194-5998(95)70246-6, 7838548.
2. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, Garden AS, Benjamin RS. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 2002, 95:377-388. 10.1002/cncr.10669, 12124838.
3. Qualman SJ, Coffin CM, Newton WA, Hojo H, Triche TJ, Parham DM, Crist WM. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998, 1:550-561. 10.1007/s100249900076, 9724344.
4. Atra A, Pinkerton R. High-dose chemotherapy in soft tissue sarcoma in children. Crit Rev Oncol Hematol 2002, 41:191-196. 10.1016/S1040-8428(01)00155-X, 11856594.
5. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. Oncologist 2005, 10:518-527. 10.1634/theoncologist.10-7-518, 16079319.
6. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005, 44:338-347. 10.1002/pbc.20227, 15503297.
7. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006, 24:3844-3851. 10.1200/JCO.2005.05.3801, 16921036.
8. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15:2207-2214. 10.1158/1078-0432.CCR-08-1306, 19318488.
9. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566. 10.1038/nm0596-561, 8616716.
10. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008, 111:1039-1043. 10.1182/blood-2007-07-103523, 17932248.
11. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
12. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006, 24:2549-2556. 10.1200/JCO.2005.04.9866, 16735708.
13. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8:3034-3038.
14. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005, 15:49-51. 10.1038/sj.cr.7290264, 15686627.
15. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol 2009, 4:444-447. 10.1097/JTO.0b013e31819d6f91, 2664527, 19333071.
16. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008, 18:87-96. 10.1016/j.gde.2008.02.001, 18406132.
17. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65:1479-1488. 10.1158/0008-5472.CAN-04-2650, 15735036.
18. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2008, 18:976-984. 10.1111/j.1525-1438.2007.01135.x, 18021219.
19. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008, 68:8039-8048. 10.1158/0008-5472.CAN-08-1712, 2671680, 18829562.
20. Grass B, Wachtel M, Behnke S, Leuschner I, Niggli FK, Schafer BW. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009, 54:873-879. 10.1111/j.1365-2559.2009.03303.x, 19469909.
21. Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups CA, Breitfeld PP, Dalton JD, Meyer WH, Khoury JD. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 2006, 19:1213-1220. 10.1038/modpathol.3800636, 16729016.
22. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006, 24:816-822. 10.1200/JCO.2005.03.4934, 16391296.
23. Andrade CR, Takahama Junior A, Nishimoto IN, Kowalski LP, Lopes MA. Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases. Braz Dent J 2010, 21:68-73. 10.1590/S0103-64402010000100011, 20464324.
24. Ricci C, Landuzzi L, Rossi I, De Giovanni C, Nicoletti G, Astolfi A, Pupa S, Menard S, Scotlandi K, Nanni P, Lollini PL. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer 2000, 87:29-36. 10.1002/1097-0215(20000701)87:1<29::AID-IJC5>3.0.CO;2-J, 10861449.
25. Ferracini R, Olivero M, Di Renzo MF, Martano M, De Giovanni C, Nanni P, Basso G, Scotlandi K, Lollini PL, Comoglio PM. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996, 12:1697-1705.
26. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998, 58:3542-3546.
27. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006, 6:637-645. 10.1038/nrc1912, 16862193.
28. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925. 10.1038/nrm1261, 14685170.
29. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008, 17:997-1011. 10.1517/13543784.17.7.997, 18549337.
30. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007, 213:316-325. 10.1002/jcp.21183, 17607709.
31. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008, 27:85-94. 10.1007/s10555-007-9107-6, 18175071.
32. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73. 10.1038/ng0597-68, 9140397.
33. Barr FG. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res 1999, 59:1711s-1715s.
34. Lukasiewicz E, Miekus K, Kijowski J, Drabik G, Wilusz M, Bobis-Wozowicz S, Majka M. Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling. Folia Histochem Cytobiol 2009, 47:485-489. 10.2478/v10042-009-0108-x, 20164036.
35. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006, 66:4742-4749. 10.1158/0008-5472.CAN-05-4292, 16651427.
36. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 2007, 13:2246-2253. 10.1158/1078-0432.CCR-06-0776, 17404109.
37. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009, 69:3021-3031. 10.1158/0008-5472.CAN-08-2881, 2871252, 19318576.